(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 May 2010 (14.05.2010)

PCT

(10) International Publication Number
WO 2010/053990 A3

(51) **International Patent Classification**:
C07K 14/575 (2006.01) *C07K 16/18* (2006.01)
C12N 15/12 (2006.01) *A61K 38/22* (2006.01)

(21) **International Application Number**:
PCT/US2009/063276

(22) **International Filing Date**:
4 November 2009 (04.11.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/111,233 4 November 2008 (04.11.2008) US
61/178,890 15 May 2009 (15.05.2009) US

(71) **Applicant** *(for all designated States except US)*: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **SWANSON, Ronald, V.** [US/US]; 13304 Barbados Way, Del Mar, CA 92014 (US). **SHANKLEY, Nigel, P.** [GB/US]; 449 Marview Lane, Solana Beach, CA 92075 (US). **MORENO, Veronica** [US/US]; 13376 Tiverton Road, San Diego, CA 92130 (US). **GENGO, Peter** [US/US]; 16735 Cabernet Circle, Morgan Hill, CA 95037 (US).

(74) **Agents**: **JOHNSON, Philip, S.** et al.; One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*


— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

[Continued on next page]

(54) **Title**: CRHR2 PEPTIDE AGONISTS AND USES THEREOF

FIG. 1A



(57) **Abstract**: The present invention relates to novel peptides that are selective corticotropin releasing hormone receptor type 2 (CRHR2) agonists and compositions thereof for the treatment, amelioration or inhibition of cardiovascular conditions, including but not limited to heart failure. The novel peptide agonist preferably comprise modifications that include pegylated peptides. Furthermore, the present invention also relates to methods for the treatment and prevention of a disease or disorder related to CRHR2 activity.

WO 2010/053990 A3

WO 2010/053990 A3

(88) Date of publication of the international search report:
1 July 2010